Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study
BackgroundBrentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1494384/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556869390270464 |
|---|---|
| author | Zhiqiang Zhao Qinchuan Yu Liping Su Jianxia He Jie Tao Yanfeng Xi Yujiao Guo Yanhong Luo Lieyang Wang |
| author_facet | Zhiqiang Zhao Qinchuan Yu Liping Su Jianxia He Jie Tao Yanfeng Xi Yujiao Guo Yanhong Luo Lieyang Wang |
| author_sort | Zhiqiang Zhao |
| collection | DOAJ |
| description | BackgroundBrentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, treated from 2020 to 2023.MethodsA multi-center observational retrospective study was conducted on patients with sALCL received BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) upfront or BV plus gemcitabine, oxaliplatin(GemOx), gemcitabine, cisplatin, dexamethasone(GDP), or isocyclophosphamide, carboplatin, etoposide (ICE)for later lines. Primary endpoints were complete response rate (CRR) and overall response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and the incidence of adverse events (AEs).ResultsAmong the 38 patients (28 newly diagnosed and 10 with refractory/relapsed disease), the ORR were 100% (with 89.3% CR) for newly diagnosed patients and 70% (with 50% CR) for refractory/relapsed patients. The median duration of response was 14 months for newly diagnosed patients and 23.8 months for those with refractory/relapsed disease. 2-year Survival rates were 100% for newly diagnosed patients and 80% for refractory/relapsed patients, with 2-year PFS rates of 92.8% and 70%, respectively. Neurological toxicities were commonly observed but resolved following the completion of treatment.ConclusionBV has proven to be effective and well-tolerated in real-world settings for the treatment of sALCL, reinforcing its potential as a promising option for first-line or subsequent therapy. The sustained efficacy observed post-CR suggests that these patients may have a prolonged disease control. |
| format | Article |
| id | doaj-art-73e6949749d1467eaebb2757af64484a |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-73e6949749d1467eaebb2757af64484a2025-01-07T05:24:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14943841494384Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective studyZhiqiang Zhao0Qinchuan Yu1Liping Su2Jianxia He3Jie Tao4Yanfeng Xi5Yujiao Guo6Yanhong Luo7Lieyang Wang8Department of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Hematology, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, ChinaDepartment of Hematology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Health Statistics, Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Health Statistics, Shanxi Medical University, Taiyuan, Shanxi, ChinaDepartment of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, ChinaBackgroundBrentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BV-based regimens in patients with sALCL, treated from 2020 to 2023.MethodsA multi-center observational retrospective study was conducted on patients with sALCL received BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) upfront or BV plus gemcitabine, oxaliplatin(GemOx), gemcitabine, cisplatin, dexamethasone(GDP), or isocyclophosphamide, carboplatin, etoposide (ICE)for later lines. Primary endpoints were complete response rate (CRR) and overall response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and the incidence of adverse events (AEs).ResultsAmong the 38 patients (28 newly diagnosed and 10 with refractory/relapsed disease), the ORR were 100% (with 89.3% CR) for newly diagnosed patients and 70% (with 50% CR) for refractory/relapsed patients. The median duration of response was 14 months for newly diagnosed patients and 23.8 months for those with refractory/relapsed disease. 2-year Survival rates were 100% for newly diagnosed patients and 80% for refractory/relapsed patients, with 2-year PFS rates of 92.8% and 70%, respectively. Neurological toxicities were commonly observed but resolved following the completion of treatment.ConclusionBV has proven to be effective and well-tolerated in real-world settings for the treatment of sALCL, reinforcing its potential as a promising option for first-line or subsequent therapy. The sustained efficacy observed post-CR suggests that these patients may have a prolonged disease control.https://www.frontiersin.org/articles/10.3389/fonc.2024.1494384/fullreal world studylymphomachinabrentuximab vedodinsystemic anaplastic large cell lymphoma(sALCL) |
| spellingShingle | Zhiqiang Zhao Qinchuan Yu Liping Su Jianxia He Jie Tao Yanfeng Xi Yujiao Guo Yanhong Luo Lieyang Wang Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study Frontiers in Oncology real world study lymphoma china brentuximab vedodin systemic anaplastic large cell lymphoma(sALCL) |
| title | Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study |
| title_full | Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study |
| title_fullStr | Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study |
| title_full_unstemmed | Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study |
| title_short | Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study |
| title_sort | real world experiences with brentuximab vedotion based regimens in systemic anaplastic large cell lymphoma a multi center retrospective study |
| topic | real world study lymphoma china brentuximab vedodin systemic anaplastic large cell lymphoma(sALCL) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1494384/full |
| work_keys_str_mv | AT zhiqiangzhao realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT qinchuanyu realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT lipingsu realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT jianxiahe realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT jietao realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT yanfengxi realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT yujiaoguo realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT yanhongluo realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy AT lieyangwang realworldexperienceswithbrentuximabvedotionbasedregimensinsystemicanaplasticlargecelllymphomaamulticenterretrospectivestudy |